We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Blog

Immunotherapy Response Prediction in Urothelial Cancer
Immunotherapy Response Prediction in Urothelial Cancer
Blog

While immunotherapy holds great promise for cancer treatment, challenges persist around limited response rate and severe immune-related adverse events. We caught up with Dr. Georg Lautscham, CEO of Protagen, to find out how the prediction of immunotherapy response can be improved for people with urothelial cancer.

Read More

Developing Therapies to Fight Cancer and Autoimmune Diseases
Developing Therapies to Fight Cancer and Autoimmune Diseases
Blog

We recently spoke to Alexis Peyroles, CEO at OSE Immunotherapeutics to hear more about the findings of their recent study, describing, for the first time ever, the in vivo MOA of interleukin 7 receptor alpha (IL-7Rα) monoclonal antibodies, suggesting therapeutic efficacy in controlling chronic inflammation.

Read More

Entering the Golden Era of Lateral Flow Diagnostics
Entering the Golden Era of Lateral Flow Diagnostics
Blog

Gold nanorods are increasingly being used in diagnostic applications, such as lateral flow assays. To learn more, we got in touch with Darren Rowles, CEO of Sona Nanotech Inc. who provides insights on diagnostic industry trends, and tells us about the source, application and production process of gold nanoparticles.

Read More

The Liquid Biopsy Trends Transforming Cancer Detection and Treatment
The Liquid Biopsy Trends Transforming Cancer Detection and Treatment
Blog

Liquid biopsy is a less invasive approach compared to traditional surgical biopsies. By collecting a simple blood sample and analyzing circulating tumor DNA (ctDNA), cancer researchers and healthcare professionals can access a myriad of information about a patient’s tumor.

Read More

Sustainability Through Innovation
Sustainability Through Innovation
Blog

With growing pressure on labs to reduce waste and improve sustainability, we spoke to the Sustainability Forum at Agilent to learn more about what the company are doing to help their customers achieve their sustainability goals.

Read More

From Growing Cells to Growing a Business
From Growing Cells to Growing a Business
Blog

How do you start, grow and run a successful life science company? To find out we spoke to Dr Yichen Shi, CEO of Axol Bioscience.

Read More

Determining Prognostic Significance of Biomarkers for Risk Stratification of Early Stage Lung Cancer
Determining Prognostic Significance of Biomarkers for Risk Stratification of Early Stage Lung Cancer
Blog

During this year’s AACR Annual Meeting we spoke to Dr. Delphine Lissa and Dr. Ana Robles from the National Cancer Institute to learn more about the team’s most recent study on the use of two specific biomarkers for risk stratification of stage I lung cancer patients.

Read More

Digital Pathology Solution Could Speed Up Prostate Cancer Diagnosis
Digital Pathology Solution Could Speed Up Prostate Cancer Diagnosis
Blog

To learn more about ContextVision, their move into the field of digital pathology, and how INIFY™ could help benefit pathologists and patients, we spoke to Lena Kajland Wilén, Director Business Unit Digital Pathology.

Read More

The STING Pathway and Cancer
The STING Pathway and Cancer
Blog

STING (stimulator of interferon genes) is a key mediator of innate immunity and the STING pathway has been shown to be involved in the induction of an anti-tumor immune response. We recently spoke to Andrea van Elsas, PhD, Chief Scientific Officer at Aduro Biotech to learn more about the company’s expertise in STING Pathway Activator technology.

Read More

HPV-Positive Oropharyngeal Cancers: Predicting Treatment Response Using ddPCR
HPV-Positive Oropharyngeal Cancers: Predicting Treatment Response Using ddPCR
Blog

During this year’s AACR Annual Meeting we spoke to Julianna Supplee, Research Technician at the Robert and Renée Belfer Center for Applied Cancer Science at Dana-Farber Cancer Institute, to learn more about the team’s most recent study on the use of plasma HPV cell-free DNA as an early predictor of treatment response in patients with advanced oropharyngeal cancer.

Read More